William A Wells

Summary

Affiliation: Global Alliance for TB Drug Development
Country: USA

Publications

  1. ncbi Tuberculosis regimen change in high-burden countries
    W A Wells
    Global Alliance for TB Drug Development, New York, New York 10005, USA
    Int J Tuberc Lung Dis 14:1538-47. 2010
  2. pmc Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making
    William A Wells
    Global Alliance for TB Drug Development, 40 Wall St, New York NY 10005 USA
    Health Res Policy Syst 9:15. 2011
  3. pmc Size and usage patterns of private TB drug markets in the high burden countries
    William A Wells
    Global Alliance for TB Drug Development, New York, New York, United States of America
    PLoS ONE 6:e18964. 2011
  4. doi Implications of the current tuberculosis treatment landscape for future regimen change
    W A Wells
    Global Alliance for TB Drug Development, New York, New York 10005, USA
    Int J Tuberc Lung Dis 15:746-53. 2011
  5. doi Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action
    William A Wells
    Global Alliance for TB Drug Development, New York, NY, USA
    Lancet Infect Dis 13:449-58. 2013

Detail Information

Publications5

  1. ncbi Tuberculosis regimen change in high-burden countries
    W A Wells
    Global Alliance for TB Drug Development, New York, New York 10005, USA
    Int J Tuberc Lung Dis 14:1538-47. 2010
    ..Experience with past tuberculosis (TB) regimen changes can guide future regimen changes...
  2. pmc Adoption of new health products in low and middle income settings: how product development partnerships can support country decision making
    William A Wells
    Global Alliance for TB Drug Development, 40 Wall St, New York NY 10005 USA
    Health Res Policy Syst 9:15. 2011
    ..At this early stage, impact data are limited. But available evidence suggests PDPs can and do play an important catalytic role in their support of country decision making in a number of target countries...
  3. pmc Size and usage patterns of private TB drug markets in the high burden countries
    William A Wells
    Global Alliance for TB Drug Development, New York, New York, United States of America
    PLoS ONE 6:e18964. 2011
    ..Tuberculosis (TB) control is considered primarily a public health concern, and private sector TB treatment has attracted less attention. Thus, the size and characteristics of private sector TB drug sales remain largely unknown...
  4. doi Implications of the current tuberculosis treatment landscape for future regimen change
    W A Wells
    Global Alliance for TB Drug Development, New York, New York 10005, USA
    Int J Tuberc Lung Dis 15:746-53. 2011
    ..The current tuberculosis (TB) treatment landscape has been studied extensively, but researchers rarely consider how it creates challenges or opportunities for future regimen change...
  5. doi Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action
    William A Wells
    Global Alliance for TB Drug Development, New York, NY, USA
    Lancet Infect Dis 13:449-58. 2013
    ..If combined judiciously during both development and implementation, new tuberculosis regimens and new DST assays have enormous potential to improve patient outcomes and reduce the burden of disease...